—

Spyre Therapeutics Inc. (SYRE) — the peer cohort

As of 2026-10-14 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Spyre Therapeutics Inc. ranks 7 of 7 in its cohort on the Closelooknet composite (23/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
SYRE Spyre Therapeutics Inc. 23 54 2 6 info 28.6%
HALO Halozyme Therapeutics Inc 74 97 94 47 ok 2%
ARGX.BR Argen-X 63 61 75 28 info 19.3%
ARGX argenx NV ADR 61 50 74 27 info 23.7%
KRYS Krystal Biotech Inc 61 68 85 16 info 13.6%
UCB.BR UCB SA 61 17 70 56 warn 29.9%
PTGX Protagonist Therapeutics Inc 59 76 61 9 info 15.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-14

Quick answers

Who are Spyre Therapeutics Inc.'s peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), Argen-X (ARGX.BR), argenx NV ADR (ARGX), Krystal Biotech Inc (KRYS), UCB SA (UCB.BR), Protagonist Therapeutics Inc (PTGX).

How does SYRE score against its peers?

Spyre Therapeutics Inc.'s composite reads 23/100, ranking 7 of 7 in its cohort as of 2026-10-14; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.